Clinical classification of pancreatitis (OF: Organ failure).
\r\n\tAs the subject of adhesives is in constant development, this book's purpose is to get together information about adhesives science and technology, recent advances, and applications that use adhesive technology. Also, to make these contents available to engineering students, engineers, researchers, and the people interested in this topic. The book is expected to present works that aim to contribute to the development of new technologies and the use of non-traditional materials in engineering.
",isbn:"978-1-83880-670-5",printIsbn:"978-1-83880-669-9",pdfIsbn:"978-1-83880-671-2",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,isSalesforceBook:!1,isNomenclature:!1,hash:"c58b7d4c17e2a202af1dc4b906b7becb",bookSignature:"Prof. António Bastos Pereira and Dr. Alexandre Luiz Pereira",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11819.jpg",keywords:"The Technology of the Adhesives, Recent Advances, New Perspectives, Structural Adhesives Bonding, Durability of Structural Adhesives, New Applications, Repair of Composites, Bonding of Composites, Experimental Mechanics Tests, Thermal Analysis, Finite Element Method, Numerical Analysis.",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"April 15th 2022",dateEndSecondStepPublish:"May 13th 2022",dateEndThirdStepPublish:"July 12th 2022",dateEndFourthStepPublish:"September 30th 2022",dateEndFifthStepPublish:"November 29th 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"12 days",secondStepPassed:!0,areRegistrationsClosed:!1,currentStepOfPublishingProcess:3,editedByType:null,kuFlag:!1,biosketch:"Dr. António Pereira is a professor and researcher, who graduated from the University of Porto, and gained experience as an engineer working at Renault, with an h-index of 23, and more than 1500 citations for 70 papers published in SCI journals.",coeditorOneBiosketch:"An active researcher in Solid Mechanics, Dr. Alexandre Luiz Pereira holds a degree in Mathematics from the State University of Rio de Janeiro, and a degree in Mechanical Engineering from the Fluminense Federal University in Brazil.",coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"211131",title:"Prof.",name:"António",middleName:"Bastos",surname:"Pereira",slug:"antonio-pereira",fullName:"António Pereira",profilePictureURL:"https://mts.intechopen.com/storage/users/211131/images/system/211131.png",biography:"Founding shareholder and Director of Martifer Group (ca. 3500 employees) (1990-1999) - was responsible for the planning and production of about 500 steel structures and industrial equipment with a total amount exceeding 100 million euros.\nAssistant Professor at the Department of Mechanical Engineering, University of Aveiro, since 2000. Board Member and Member of the Executive Committee at the Department of Mechanical Engineering, University of Aveiro (2011 – 2015), currently Director of TEMA - Centre for Mechanical Technology and Automation.\nHis main research area has been mechanics of composite materials, with particular emphasis on delamination fracture mechanics. He has published 44 papers in SCI journals and has delivered 30 presentations at international conferences. His h-index at scopus is 16 with more than 770 citations.",institutionString:"University of Aveiro",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"University of Aveiro",institutionURL:null,country:{name:"Portugal"}}}],coeditorOne:{id:"452095",title:"Dr.",name:"Alexandre Luiz",middleName:null,surname:"Pereira",slug:"alexandre-luiz-pereira",fullName:"Alexandre Luiz Pereira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003LeECuQAN/Profile_Picture_1642158596909",biography:"Alexandre Luiz Pereira is Ph.D. in Mechanical Engineering and Materials Technology. During the period of the Ph.D., he did a Postgraduate Internship at the Department of Mechanical Engineering at the University of Aveiro/Portugal (UA). Since 2014 he has been a professor and researcher at the Federal Center of Technological Education in Rio de Janeiro (CEFET/RJ). He is currently the coordinator of the Mechanical Engineering course at the CEFET/RJ Campus Angra dos Reis. His main research areas focus on the study of materials technology, from structural and hybrid composites, hyperelastic materials, and adhesives joints.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:null},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"14",title:"Materials Science",slug:"materials-science"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"444312",firstName:"Sara",lastName:"Tikel",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/444312/images/20015_n.jpg",email:"sara.t@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"7610",title:"Renewable and Sustainable Composites",subtitle:null,isOpenForSubmission:!1,hash:"c2de26c3d329c54f093dc3f05417500a",slug:"renewable-and-sustainable-composites",bookSignature:"António B. Pereira and Fábio A. O. Fernandes",coverURL:"https://cdn.intechopen.com/books/images_new/7610.jpg",editedByType:"Edited by",editors:[{id:"211131",title:"Prof.",name:"António",surname:"Pereira",slug:"antonio-pereira",fullName:"António Pereira"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6320",title:"Advances in Glass Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6d0a32a0cf9806bccd04101a8b6e1b95",slug:"advances-in-glass-science-and-technology",bookSignature:"Vincenzo M. Sglavo",coverURL:"https://cdn.intechopen.com/books/images_new/6320.jpg",editedByType:"Edited by",editors:[{id:"17426",title:"Prof.",name:"Vincenzo Maria",surname:"Sglavo",slug:"vincenzo-maria-sglavo",fullName:"Vincenzo Maria Sglavo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6517",title:"Emerging Solar Energy Materials",subtitle:null,isOpenForSubmission:!1,hash:"186936bb201bb186fb04b095aa39d9b8",slug:"emerging-solar-energy-materials",bookSignature:"Sadia Ameen, M. Shaheer Akhtar and Hyung-Shik Shin",coverURL:"https://cdn.intechopen.com/books/images_new/6517.jpg",editedByType:"Edited by",editors:[{id:"52613",title:"Dr.",name:"Sadia",surname:"Ameen",slug:"sadia-ameen",fullName:"Sadia Ameen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6188",title:"Solidification",subtitle:null,isOpenForSubmission:!1,hash:"0405c42586170a1def7a4b011c5f2b60",slug:"solidification",bookSignature:"Alicia Esther Ares",coverURL:"https://cdn.intechopen.com/books/images_new/6188.jpg",editedByType:"Edited by",editors:[{id:"91095",title:"Dr.",name:"Alicia Esther",surname:"Ares",slug:"alicia-esther-ares",fullName:"Alicia Esther Ares"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9393",title:"Engineering Steels and High Entropy-Alloys",subtitle:null,isOpenForSubmission:!1,hash:"d33466a3272f97353a6bf6d76d7512a5",slug:"engineering-steels-and-high-entropy-alloys",bookSignature:"Ashutosh Sharma, Zoia Duriagina, Sanjeev Kumar",coverURL:"https://cdn.intechopen.com/books/images_new/9393.jpg",editedByType:"Edited by",editors:[{id:"145236",title:"Dr.",name:"Ashutosh",surname:"Sharma",slug:"ashutosh-sharma",fullName:"Ashutosh Sharma"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6802",title:"Graphene Oxide",subtitle:"Applications and Opportunities",isOpenForSubmission:!1,hash:"075b313e11be74c55a1f66be5dd56b40",slug:"graphene-oxide-applications-and-opportunities",bookSignature:"Ganesh Kamble",coverURL:"https://cdn.intechopen.com/books/images_new/6802.jpg",editedByType:"Edited by",editors:[{id:"236420",title:"Dr.",name:"Ganesh",surname:"Kamble",slug:"ganesh-kamble",fullName:"Ganesh Kamble"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6656",title:"Phase Change Materials and Their Applications",subtitle:null,isOpenForSubmission:!1,hash:"9b257f8386280bdde4633d36124787f2",slug:"phase-change-materials-and-their-applications",bookSignature:"Mohsen Mhadhbi",coverURL:"https://cdn.intechopen.com/books/images_new/6656.jpg",editedByType:"Edited by",editors:[{id:"228366",title:"Dr.",name:"Mohsen",surname:"Mhadhbi",slug:"mohsen-mhadhbi",fullName:"Mohsen Mhadhbi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6805",title:"Electrical and Electronic Properties of Materials",subtitle:null,isOpenForSubmission:!1,hash:"f6b6930e7ae9d0704f68b5c180526309",slug:"electrical-and-electronic-properties-of-materials",bookSignature:"Md. Kawsar Alam",coverURL:"https://cdn.intechopen.com/books/images_new/6805.jpg",editedByType:"Edited by",editors:[{id:"199691",title:"Dr.",name:"Md. Kawsar",surname:"Alam",slug:"md.-kawsar-alam",fullName:"Md. Kawsar Alam"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8417",title:"Recent Advances in Boron-Containing Materials",subtitle:null,isOpenForSubmission:!1,hash:"3737be3f785ef9d8b318571ab474f407",slug:"recent-advances-in-boron-containing-materials",bookSignature:"Metin Aydin",coverURL:"https://cdn.intechopen.com/books/images_new/8417.jpg",editedByType:"Edited by",editors:[{id:"27070",title:"Prof.",name:"Metin",surname:"Aydin",slug:"metin-aydin",fullName:"Metin Aydin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8812",title:"Contemporary Topics about Phosphorus in Biology and Materials",subtitle:null,isOpenForSubmission:!1,hash:"86c427901f631db034a54b22dd765d6a",slug:"contemporary-topics-about-phosphorus-in-biology-and-materials",bookSignature:"David G. Churchill, Maja Dutour Sikirić, Božana Čolović and Helga Füredi Milhofer",coverURL:"https://cdn.intechopen.com/books/images_new/8812.jpg",editedByType:"Edited by",editors:[{id:"219335",title:"Dr.",name:"David",surname:"Churchill",slug:"david-churchill",fullName:"David Churchill"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"75376",title:"Necrotizing Pancreatitis: Step Up Approach",doi:"10.5772/intechopen.96196",slug:"necrotizing-pancreatitis-step-up-approach",body:'Acute pancreatitis (AP) is a inflamatory condition of the pancreatic gland with or without involvement of peripancreatic tissues and distant organs [1]. The incidence of AP is 20–35 cases per 100,000 inhabitants per year, with an overall mortality of 2–10%. In recent decades the incidence of AP has increased globally and is expected to increase even more. The most common cause is biliary lithiasis, which accounts for about 40–50%. The alcohol, predominantly in males, is the second most common cause, at over 30% and 10–25% the cause is unknown.
Most cases follow a mild, self-limiting course, but 10–20% of patients develop a severe form with systemic and local life-threatening complications of pancreatic and peripancreatic necrosis come about 20–40% of patient with severe AP and aggravate organ functions [2, 3, 4, 5, 6]. Infected necrotic tissue is defined as a gram positive of pancreatic or peripancreatic necrotic tissue obtained by means of fine-needle aspiration or from the first drainage procedure or operation, or the presence of gas in the fluid collection on contrast-enhanced computer tomography (CT). Suspected infected necrosis is defined as persistent sepsis or progressive clinical deterioration in the intensive care unit without documentation of infected necrosis. Failure of one or more organs occurs in 40% of these patients with pancreatic necrosis and on rare occasions it can also occur in cases without necrosis. Mortality amounts to 30% when infection of the pancreatic and/or peripancreatic necrosis is present [7].
The traditional approach to the treatment of necrotizing pancreatitis with secondary infection of necrotic tissue is open necrosectomy to remove the infected necrotic tissue. But this is associated with high rates of complications, death and pancreatic insufficiency. The studies show that death rates from open pancreatic necrosectomy are between 10–40% [8, 9, 10]. The management of AP has evolved greatly in recent years thanks to a better understanding of pathophysiology, the improvement of the therapeutic arsenal of intensive care units, nutritional support, conventional and interventional radiology techniques and surgical treatment. Recently, a randomized trial called “PANTER” very well designed study by the Dutch Pancreatitis Study Group, demonstrated the benefits of sequential treatment in cases of infected necrosis (“Step an approach”) compared to traditional open necrosectomy, showing less morbidity and lower costs [7]. The sequential treatment is an alternative to open necrosectomy, less invasive techniques, including percutaneous drainage, endoscopic (transgastric) drainage, and minimally invasive retroperitoneal necrosectomy. The importance of step up approach is that the first step is percutaneous or endoscopic drainage of the collection of infected fluid to mitigate sepsis and this step may postpone or even obviate surgical necrosectomy. If the drainage does not take to clinical recovery, the next step is minimally invasive retroperitoneal necrosectomy. With this approach, up to 35% of patients can be treated only with drainage, to avoid necrosectomy and to reduce the percentage of complications [7].
Before to describe the management of infected necrosis, we need to know the classification of acute pancreatitis [11, 12].
The severity of acute pancreatitis can be defined as mild, moderately severe, or severe according to the revised Atlanta classification (Table 1).
Mild acute pancreatitis: absence of organ failure or local and/or systemic complications.
Moderate acute pancreatitis: organ failure, and/or transient local or systemic complications that resolve within 48 hours maximum. Mortality in this group is less than 8%.
Severe acute pancreatitis: continued organic failure over 48 hours accompanied by local and/or systemic complications. Mortality in this group is 36–50%.
Potentially severe acute pancreatitis: organ failure or a warning sign at the beginning of its evolution (Table 2), and therefore requires closer monitoring, to anticipate the development of transitory, persistent organ failure or pancreatic infection. The need to detect and treat patients who are developing organ failure with invasive resuscitation measures as early as possible has been demonstrated with a strong degree of recommendation and a high level of evidence.
Mild acute pancreatitis | absence of OF or local and/or systemic complications |
Moderate acute pancreatitis | OF and/or transient local or systemic complications <48 hours |
Severe acute pancreatitis | OF and/or transient local or systemic complications >48 hours |
Potentially severe acute pancreatitis | OF or warning pancreatic sign (Table 2) |
Clinical classification of pancreatitis (OF: Organ failure).
Characteristics of patient | Analitics parameters | Radiological Features | Forecast scales |
---|---|---|---|
Age > 50 years | BUN >20 mg/dl | Pleural Effusion | APACHE II >2 |
BMI < 30 | Hematocrit >44% | Pancreatic collections or peritoneal free liquid. | Ranson-Glasgow >3 |
Deteriorate state of mind | Procalcitonin >0.5 ng/ml in the first 48 hours | ||
Comorbidity | Reactive C protein >150 mgl, or progressive elevation in 48 hours) | ||
Abdominal defense | Elevated Creatinine |
Warning pancreatic sign (BMI: Body mass index, BUN: Blood urea nitrogen).
There is another classification of AP severity that adds another step to the severity of these processes: Acute critical pancreatitis, in which persistent organ failure (OF) coexists with necrosis infection, described in 2012 by Petrov et al.
Classification according to radiological characteristics according to the Atlanta Classification:
Interstitial o edematous pancreatitis: the pancreas is enlargement due to inflammation or edema. The pancreatic parenchyma shows homogeneous enhancement, and the peripancreatic fat usually shows some inflammatory changes. Besides there may be some peripancreatic fluid. The clinical symptoms of interstitial o edematous pancreatitis usually resolve within the first week.
Necrotising pancreatitis: about 5–10% of patients develop necrosis of the pancreatic parenchyma, the peripancreatic tissue or both. Necrotising pancreatitis shows necrosis involving the pancreas and peripancreatic tissues and less commonly as necrosis of only the peripancreatic tissue or pancreatic parenchyma alone. The natural history of pancreatic and peripancreatic necrosis is variable, because it may remain solid or liquefy, remain sterile or become infected, persist or disappear over time. The presence of infection can be proved by extraluminal gas in the pancreatic and/or peripancreatic tissues or when percutaneous fine-needle aspiration is positive for bacteria and/or fungi on Gram.
Local complications of acute pancreatitis:
Acute peripancreatic liquid collection: presence of peripancreatic liquid in the context of edematous interstitial pancreatitis. It occurs in the first 4 weeks and is characterized by the appearance of homogeneous fluid adjacent to the pancreas and its fascial planes without the presence of a wall.
Pancreatic pseudocyst: well-defined collection with a wall formed without a solid component that occurs after 4 weeks of oedematous interstitial pancreatitis.
Acute necrotic collection: collection with a solid and liquid component that appears in the context of necrotizing pancreatitis and can affect the pancreas and surrounding tissues. It has no wall (Figure 1).
Encapsulated pancreatic necrosis (Walled-off necrosis): is an acute necrotic collection, mature, encapsulated with a well-defined inflammatory wall, and which appears 4 weeks after the onset of necrotic pancreatitis. It is heterogeneous and can affect peripancreatic tissues.
In the CT scan image we can see acute pancreatic collection without radiological signs of infection.
The most important consideration in treating local complications is to demonstrate the presence of infection.
Because the majority of patients with sterile pancreatic or peripancreatic necrosis can be treated conservatively, regardless of the size and extension of the collections.
Drainage in a sterile collection can produce iatrogenic infection, worsening the patient’s prognosis. Could only be an alternative in those patients with persistent symptoms such as abdominal pain, duodenal obstruction or jaundice [13, 14].
Necrosis infection usually occurs within 2–3 weeks of the onset of BP. Successive CT scans should be performed according to the evolution of the patient and not in a programmed way. Early onset is rare, and should be suspected if SIRS persists or recurs after 10 days-2 weeks [15]. Therefore, the suspicion of infection will be made according to the bad evolution of the patient: fever, increase of leukocytes, elevation of PCR and/or procalcitonin, sudden resurgence or worsening of FO. This clinical evolution can be given by sterile necrosis, and it is often a challenge to differentiate whether we are dealing with an infected necrosis or not. Given this scenario, CT has high sensitivity to detect signs of infection (gas in the collection only appears in 12–22% of infected cases (Figure 2). However the signs of infection are usually sufficient to diagnose a secondary infection of pancreatic or peripancreatic necrosis. In case of diagnostic uncertainty, a positive gram stain or culture of the necrotic collection, obtained by transabdominal fine needle aspiration, may be necessary. However, the disadvantage of fine needle aspiration in this scenario is the false negative rate of 25% [16].
CT scan image showing radiological signs of pancreatic necrosis due to the presence of gas in the acute necrotic collection.
We present the management of acute pancreatitis with signs of infected necrosis. For this we will describe each of the therapeutic options in the philosophy of step up approach (Algorithm 1).
The first step is the administration of broad- spectrum antibiotic therapy [16]. The germs most involved are
Recommended empirical therapy:
Meropenem: 1 gr. e.v. every 8 hours
Moxifloxacin: 400 mg e.v. every 24 hours
Once the final result of the cultivation is obtained, the anti-biotherapy will be adapted. A small proportion of patients can be managed with supportive care and antibiotics alone, without the need for additional invasive interventions [17].
Open surgery in the treatment of infected pancreatic necrosis has been replaced by the minimally invasive approach. The multi-centre randomized clinical trial PANTER [18] showed that step up approach treatment of necrotising pancreatitis reduces patient mortality, multiorgan failure, costs and late surgical complications. The step-up approach consists of percutaneous catheter drainage or endoscopic transluminal drainage, followed by minimally invasive necrosectomy only when clinically required, is the current standard treatment [19].
Secondary infection of pancreatic or peripancreatic necrosis can occur in the first 3 weeks after onset of disease, and long-term administration of antibiotics might lead to increased incidence of fungal infections and antibiotic resistance [15, 20]. The benefit of early drainage has been demonstrated, although its indication has to be established after confirmation of infection, otherwise we could be infecting a sterile collection. The ideal percutaneous drainage would be via the retroperitoneal route and on the left side, which would facilitate subsequent minimally invasive surgical access if necessary. Current evidence shows that 35% of patients treated with percutaneous drainage in this phase will not require additional surgical necrosectomy and that up to 50% in series where a progressive increase in the diameter of the drainage catheter is used [19]. Once the radiological drainage was carried out, the therapeutic sequence would be as follows:
if poor evolution persists after 48 hours and the patient’s conditions permit it, a new drainage with a larger diameter would be attempted.
if the poor clinical condition is maintained, despite the use of larger drains, surgical drainage should be carried out.
The current tendency is to be as non-invasive as possible. Several techniques have been described that will be developed in our service gradually, such as video assisted retroperitoneal access that presents significantly lower rates of abdominal complications than the most classic techniques. This technique uses radiological drainage as a guide to the collection, hence the importance of placing it on the left side as long as possible (Figure 3).
CT scan image showing left retroperitoneal collection with easy access for percutaneous drainage. And it will allow a retroperitoneal laparoscopic approach.
After 4 weeks, in addition to percutaneous radiological drainage in case of infection as mentioned above, endoscopic drainage could be evaluated. Generally, at this stage an inflammatory wall would already be formed consistent enough to withstand transgastic endoscopic drainage (walled-off necrosis).
The step-up approach can be done both surgically and endoscopically. The two different approaches have been compared with each other in two randomized trials. The first is the TENSION trial that concluded that the endoscopic step-up approach was not superior to the surgical step-up approach in reducing major complications or death but the rate of pancreatic fistulas and length of hospital stay were lower in the endoscopy group [21]. The second trial is MISER [22] randomizade controlled trial showed that an endoscopic transluminal approach for infected necrotizing pancreatitis, compared with minimally invasive surgery, significantly reduced major complications, lowered costs, and increased quality of life.
In short, the endoscopic staggered approach has become the approach of choice according to recent studies for the management of infected necrotizing pancreatitis [23, 24, 25, 26, 27]. However it could not be feasible in all patients. It depends on the anatomical location of the infected necrotic collections, availability of technique and experience of the center and trained personnel (Figure 4). The option of combined endoscopic transluminal and percutaneous catheter drainage, which is also known as dual-modality drainage, should not be overlooked in patients with large collections extending into the paracolic gutters or the pelvic region.
CT scan image showing infected acute necrotic collection of retrogastric location. We can see metallic stent drainage inside the collection.
Currently, the stents placed between gastric light and the infected collection are metallic (Figure 5). They were created in 2011 and replaced with plastic stents. These stents provide wider light that allows better drainage and facilitates transluminal necrosectomy. The best available evidence comes from a randomized trial that compared the efficacy of metal and plastic stents in the drainage of infected pancreatic necrosis. The study found no differences in the median number of procedures, readmissions, and length of hospital stay [28]. Although endoscopic treatment with metal stents was associated with higher procedure costs. In addition, adverse effects such as stent migration were observed. Therefore, the latest consensus guidelines recommend metal stents or double pigtail plastic stents for endoscopic transluminal drainage and removal after 4 weeks to minimize the risks of complications [28, 29].
Endoscopy image showing metallic stent that communicates the gastric camera and the acute necrotic collection.
Between 23–47% of patients will improve only with percutaneous or endoscopic drainage. But in those patients with persistent disease, surgery is the next step [18, 30, 31]. Objectives of surgical debridement are to control the source of infection and reduce the burden of necrosis, while minimizing the proinflammatory damage of the intervention itself on the weakened patient. The current trend is to be as non-invasive as possible. We will start with a videoassisted retroperitoneal approach and if it is not enough we will perform necrosectomy by open approach [32].
Several techniques have been described, such as video assisted retroperitoneal access that presents significantly lower rates of abdominal complications than the most classic techniques. This technique uses radiological drainage as a guide to the collection, hence the importance of placing it on the left side as long as possible. The tract formed by the anterior drainage is used to access the retroperitoneal space for intracavitary videoassisted necrosectomy (Figure 6). Traditional laparoscopic instruments are used under direct vision (Figures 7 and 8). We can leave well-positioned drains that allow washing. The process may be repeated if necessary to remove the infected pancreatic necrosis. It should be noted that the VARD approach is more effective in treating central to left parietocolic infected pancreatic necrosis. However, it will be more difficult to access the necrosis located to the right of the mesenteric vessels [32] (Figure 9).
CT scan image showing infected acute necrotic collection on the left flank. It allows a percutaneous drainage approach and subsequent laparoscopic retroperitoneal access.
Using left retroperitoneal percutaneous drainage as a guide, we can access it by minimally invasive approach. We observed laparoscopic trócar through which we introduced camera, vacuum cleaner and laparoscopic tweezers.
Image of CT scan that objective retroperitoneal necrotic collection with drainage inside placed by laparoscopic retroperitoneal access.
CT scan showing surgical drainage on the right flank by laparoscopic retroperitoneal access.
The concept is similar to endoscopic trasngastic drainage. It can be performed by open or laparoscopic approach. An anterior gastrostomy is required to access the posterior face of the stomach and then the infected cavity. It is especially useful in central collections that do not affect the flanks (Figure 10). It is advisable to leave a drain inside the cavity for washing. There are studies of small sample size that demonstrate the efficacy of the technique with low morbidity [33, 34, 35].
CT scan image showing collection near the gastric posterior wall that would allow a transgastic approach.
If these methods are unable to control the infectious condition, the patient’s deterioration, despite good drainage, including minimally invasive surgical drainage, would be indicated to the open surgical approach. The mortality of patients with infected necrosis is greater than 30%, as we have commented, the delay in surgery as much as possible will be more beneficial for the patient in terms of mortality and morbidity. Early debridement, and especially sterile necrosis, leads to a significant increase in mortality. Therefore, these techniques are reserved when everything else has not been enough [36, 37]. We have widely described open necrosectomy techniques. None of them has been shown to be clearly superior to the other due to the lack of randomized studies, but the ones that offer the best results are:
Open surgical necrosectomy with closed packing: described by A.L. Warshaw, with lower mortality rates than the other techniques (10%) and that would be indicated in limited necrosis.
Open surgical necrosectomy with closed postoperative lavage: in case of more extensive necrosis. The recommended wash would be 12–24 liters every 24 hours with potassium-free dialysis fluid.
Open surgical necrosectomy with open packing: it is the technique with the highest morbidity-mortality, but it would be indicated in cases with more extensive necrosis that exceed the colon.
Vacuum Assisted Closure therapy will be used as a temporary closure in cases where closure of the abdominal pare is impossible or in cases of abdominal compartment syndrome.
Current comparative studies, with the exception of randomized trials [18], should be interpreted with caution, given the severity of the often higher disease in patients undergoing open debridement. Open debridement is indicated in patients with a high necrosis load that is diffusely distributed throughout the abdomen and that do not respond to staggered handling [32].
RAMSON: Prognostic scale in acute pancreatitis (Table 3).
on admission | age > 55 yerars | age > 55 years |
white blood cell count>16.000 mm3 | blood glucose>10 mmol/l | |
blood glucose >200 mg % | LDH > 600 UI/l | |
LDH > 400 UI/l | AST > 100 UI/l | |
AST > 200 UI/l | serum urea>16 mmol/l | |
Arterial PaO2 < 60% | ||
serum Calcium<8 mg/dl | ||
serum albumin<3,2 mg/l | ||
white blood cell count>15.000 mm3 | ||
within 48 hours | hematocrit fall>10% | |
blood urea nitrogen rise >5 mg% | ||
Arterial PaO2 < 60 mmHg | ||
base deficit>4 mEq/l | ||
fluid sequestration >6 liters | ||
serum calcium<8 mg% |
Ramson and Glasgow prognostic scale.
GLASGOW: Prognostic scale in acute pancreatitis (Table 3).
Zero to do criteria met indicates mild pancreatitis; 3 or more criteria severe pancreatitis.
According to the number of criteria the rate of mortality is: 0–2 mortality >2%; 3–5 mortality 10–20%; 6–7 mortality 50–60%; > 7 mortality 70–90%.
Patients with diagnosis of acute necrotizing pancreatitis should be treated in centers with high experience by specialists in pancreatic surgery, endoscopists and radiologist experienced. It is essential the presence of a team of intensive doctors or anesthesiologists especially in the first weeks of evolution. Despite these measures the morbidity and mortality in these patients is still high, so we must try to reduce it with a correct management and applying the “step up approach”. The sequential treatment is an alternative to open necrosectomy, including percutaneous drainage, endoscopic (transgastric) drainage, and minimally invasive retroperitoneal necrosectomy. With this approach, up to 35% of patients can be treated only with drainage, to avoid necrosectomy and to reduce the percentage of complications.
Our thanks to the Biliopancreatic Surgery Unit that through effort and study have created a protocol for the management of severe pancreatitis. The team is made up of expert pancreatic surgeons, intensivist physicians, anesthesiologists, endoscopists with experience in echoendoscopy and radiologists specializing in the abdomen. Together we will continue to train for the good of our patients.
The authors declare no conflict of interest.
None
Algorithm 1. Management of acute pancreatitis with infected pancreatic necrosis. acute pancreatitis computer tomography organ failure body mass index blood urea nitrogen lactate dehydrogenase aaspartate ainotranferase blood pressure from oxygen video assited retroperitoneal debridement acute physiology and cronic health evaluation (Figure 11).
APACHE SCALE. Health care Financ rev. 1984 Nov; 1984(Suppl): 91–105.
Food quality is a very broad concept, whose definition presents a complex and dynamic character, which varies according to the time interval and the geographic location.
From the consumer’s point of view, quality is intrinsically linked to health, well-being, and sensory aspect of the products, which makes this concept quite diffuse and subjective [1, 2].
The measurability of the food quality parameter can allow its conversion to be more objective. For producers, the precision in the parameterization of this concept is very important, because the consumer’s perception of quality greatly affects the purchase decision, which in Europe is directly correlated with information subjective [2].
According to Tothill and Stephen [3], a large investment is needed in terms of providing relevant information and industrial marketing practices. This gap has been reduced with the regulation on labeling, requiring the definition of consistent norms and standards, a rigorous food quality control process in order to keep the consumer safe [4], and confident in their decision to purchase the product. This point is in line with Organization for Economic Co-operation and Development (OECD) indications, as there are data indicating that the content of food labels influences consumer behavior more than energy efficiency labeling [5].
Food quality control involves the specification of ingredients and the consequent physical, chemical, and microbiological characterization of food and food products [6].
All food quality control is carried out, using acceptable and well-established methodologies, in order to maintain product characteristics, but is increasingly associated with food safety, for the prevention of chemical and biological hazards that may result in contamination [6, 7].
Since food quality and safety are two increasingly interconnected domains, it is of great value to identify which constituents in food make it unfeasible to consume. These components, called contaminants, are increasingly regulated and controlled, because their improper consumption can interfere with consumer health.
In 1963, a harmonized international collection of food standards, guidelines, and codes of practice was created by the Codex Alimentarius Commission, a joint intergovernmental body of the Food Agriculture Organization (FAO) and the World Health Organization (WHO), to protect consumer health and ensure fair food trade practices.
Since contaminants are defined as substances that are not intentionally added to food and may result from various stages such as production, packaging, transport or storage, or environmental factors, the Codex Committee on Contaminants in Food (CCCF) establishes and endorses maximum allowable levels or guideline levels for naturally occurring contaminants and toxins in food and feed. Codex has established 17 maximum levels for these types of substances, including some hazardous metals, mycotoxins produced by certain fungi, and radionuclides [8].
EU legislation, through its Regulations 315/93/EEC [9], 1881/2006 [10], and amendments, imposes procedures for the determination of contaminants and their maximum levels. Thus, in this issue we will cover three main topics related to the intrinsic quality of food, namely heavy metals, polycyclic aromatic hydrocarbons (PAHs), mycotoxins.
There is a wide variety of synthetic and natural organic pollutants found in the environment, contaminating air, water, soils, and therefore, animals and plants, many of them are used for human food. However, within this vast array are the PAHs that present a great structural diversity, possessing two or more benzene rings. These hydrocarbons can be produced by pyrolysis or incomplete combustion of carbon compounds, such as oil and coal [11, 12].
Highly important and problematic is the fact that this group of aromatic organic compounds can be teratogenic, carcinogenic, and mutagenic, can cause serious problems in human health, and can therefore be used as a marker for the occurrence of polycyclic aromatic hydrocarbons in food [13]. Processing of food, such as smoking, heating, and drying processes, and cooking at high temperatures are the major sources of contamination by PAHs because those processes allow combustion products to come into contact with food. High levels of PAH are found in dried fruits, olive pomace oil, teas, smoked fish, grape seed oil, smoked meat products, fresh mollusks, and condiments [12, 14].
Existence of PAH and its relationship with human health and nutrition is an issue that goes back more than half a century. To protect public health, maximum levels are also necessary for foods where environmental pollution may cause high levels of contamination especially in fish and fishery products that contact contaminated water [15]. The detection, identification, monitoring, and regulation that exist today rely on identities such as the Joint FAO/WHO Expert Committee on Food Additives (JECFA), the European Food Safety Authority (EFSA), the Scientific Committee on Food (SCF), the United States Environmental Protection Agency (U.S. EPA), the International Agency for Research on Cancer (IACR), and the International Programme on Chemical Safety (IPCS), that have joined forces to raise alert to this issue [16].
Based on the evaluation of PAHs, in 2002, the European Union through SCF concluded that 15 PAHs, namely benz[a]anthracene, benzo[b]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, benzo[ghi]perylene, benzo[a]pyrene, chrysene, cyclopenta[cd]pyrene, dibenzo[a,h]anthracene, dibenzo[a,e]pyrene, dibenzo[a,h]pyrene, dibenzo[a,i]pyrene, dibenzo[a,l]pyrene, indeno[1,2,3-cd]pyrene, and 5-methylchrysene showed evidence of mutagenicity, genotoxicity [14]. In 2005, EFSA concluded that benzo[a]pyrene could be used as marker to exposure to, and effect of, genotoxic and carcinogenic PAHs. Later, in 2008, the evaluations showed that 50% of the thousands of samples analyzed contained benzo[a]pyrene, but that 30% of the samples that showed carcinogenic properties contained no benzo[a]pyrene. Based on these and other findings, the CONTAM Panel concluded that the risk characterization should be based upon oral carcinogenicity data of eight PAHs, explicitly benzo[a]pyrene, benz[a]anthracene, benzo[b]fluoranthene, benzo[k]fluoranthene, benzo[ghi]perylene, chrysene, dibenz[a,h]anthracene, and indeno[1,2,3-cd]pyrene (PAH8). These polycyclic aromatic hydrocarbons either individually or in a combination were considered possible indicators of the carcinogenic potency in food. In addition to the effects of the sum of PAH8, the sum of benzo[a]pyrene, chrysene, benz[a]anthracene, and benzo[b]fluoranthene (PAH4), as well as the sum of benzo[a]pyrene and chrysene (PAH2), and the correlation between PAH2, PAH4, and PAH8 were calculated. The CONTAM Panel later concluded that benzo[a]pyrene is not an appropriate indicator for PAH in food and that PAH4 and PAH8 are the most appropriate indicators of PAH in food, with PAH8 not providing much added value compared with PAH4, which are presented in Table 1 [16, 17].
Polycyclic aromatic hydrocarbons (PAH4) and structures.
The foods with maximum levels of PAH4, benzo(a)pyrene, benzo(a)anthracene, benzo(b)fluoranthene and chrysene, above those laid down in EU Regulations 315/93/EEC [9], and 1881/2006 [10] may not be consumed nor used for the edible part of the food. However, recently new data have been collected in order to obtain more useful information on PAHs. An example of this is the new regulated values for powders of food of plant origin used for the preparation of beverages, contained in Regulation 2020/1255 [18], where the maximum thresholds of 10 μg/kg for benzo(a)pyrene and 50 μg/kg for the sum of benzo(a)pyrene, benz(a)anthracene, benzo(b)fluoranthene, and chrysene are established. The same regulation warns of the need to look for new alternative smoking practices to reduce PAH contaminants. This last point is illustrative of the regulators’ concern for maintaining food safety, but also shows the concern for food quality, which has great weight at consumer level and also directly in the production and marketing of smoked products and their derivatives.
European Union also establishment, in Commission Regulation (EC) No 1881/2006 [10], the maximum levels for cadmium (Cd), lead, mercury (Hg), inorganic tin (Sn), and arsenic (As), knowing that the exposure of these heavy metals may lead to oxidation stress, which may induce DNA damage, protein modification, lipid peroxidation, and consequently, toxicity in plants and humans [19, 20]. It is important to mention, from a chemical point of view, that arsenic, although being classified as a nonmetal, is included in the group of heavy metals when it comes to environmental parameters. Consequently, from this point on we will roughly call arsenic a heavy metal [21].
For these metallic elements, the European Commission, through Regulation EC No 1881/2006 [10], sets the maximum levels for certain contaminants in foodstuffs, has fixed the tolerable weekly intake (PTWI) of mercury and lead at 1.6 and 25 μg/kg body weight (bw), respectively, Regulation EC No 488/2014 [22] sets the tolerable weekly intake (TWI) at 2.5 μg/kg bw/week for cadmium, and EC Regulation 2015/1006 [23] annexed to the Regulation EC No 1881/2006 [10], estimated maximum dietary exposures BMDL01 between 0.3 and 8 μg/kg bw/day for arsenic.
Chemical contamination is a consumer concern, but microbiological is the greatest one [24]. The presence of mycotoxins in food and feed is an important concern of the authorities concerning food safety and quality, as their presence may have an important impact on the health of consumers both in the short term and in the long term [25]. Due to its toxicity, the Rapid Alert System for Food and Feed (RASFF) in 2017 considered mycotoxins among the top 10 risk categories in terms of contaminants for food and products [26].
Mycotoxins are products resulting from the secondary metabolic by certain filamentous fungi, they are not essential for their growth and reproduction but can cause biochemical, physiological, and pathological changes in many species [27]. Fungi frequently occur in several crops, such as wheat, corn, soybeans, sorghum, and dried fruits, as well as in derived products used in human food and feed; they can accumulate in maturing products already in the field, or during harvesting, in transportation or also in storage [28, 29, 30].
Depending on microclimatic conditions, such as moisture content, temperature, pH value, and food matrix composition, fungi can produce more than one mycotoxin, and some mycotoxins are produced by more than one fungal species [31, 32]; once produced they can be modified as a result of interactions between fungi and host or during processing, so when humans or animals are exposed to several mycotoxins simultaneously synergistic effects can be observed [25]. Most mycotoxins are low-molecular-weight compounds (less than 1000 Daltons) [33], highly liposoluble, very stable, and can accumulate over time both during crop growth and post-harvest. The European Union authorities produce documentation regarding a comprehensive strategy to be implemented by the food production chain in terms of correct pre-harvest management and post-harvest strategies and also on sanitary conditions as well on the technology and operating conditions in live cycle products [25] to prevent and minimize the contents of mycotoxins as a food contaminant [34].
The main fungi producing mycotoxin belonging to the genera
We can also distinguish between the field toxins, present in the crops, represented mainly by Fusarium deoxynivalelol mycotoxins (DON), zearalenone, fumonisins, and T-2/HT-2 toxins and the storage toxins of which the main ones are aflatoxins (Aflatoxin B1) and ochratoxins (Ochratoxin A).
Human and animals can be exposed to mycotoxins through oral (i.e., dietary consumption) inhalation (dust), and dermal routes, due to their chemical characteristics they are easily absorbed and undergo systemic distribution. In systemic circulation they reach several organs, such as the liver, kidneys, nervous system, and immunological system [33], causing alterations in the immunological response carcinogenicity, teratogenicity, hepatotoxicity, neurotoxicity, nephrotoxicity, reproductive and developmental toxicity, gastrointestinal disorders, among others [32, 35].
Considering that carcinogenic and mutagenic mycotoxin actions are the main health risk in prolonged exposure, Claeys et al. in their systematic review in 2020 [36] classify the main mycotoxins according to International Agency for Research on Cancer (IRCA) criteria into three groups: group 1—The agent is carcinogenic to humans; group 2A—The agent is probably carcinogenic to humans; group 2B—The agent is possibly carcinogenic to humans; group 3—The agent is not classifiable as to its carcinogenic to humans [37]. In Table 2, we gather the IARC toxic effects by Claeys et al. with disease-related problem, fungal species, their occurrence, and the limited daily intake, when studied.
Mycotoxins | Toxic effect | Disease-related problem/targeting system | Fungal species | Frequently contaminated products | Maximum tolerable daily intake |
---|---|---|---|---|---|
Aflatoxins B1, B2, G1, G2 (AFB1, AFB2, AFG1, AFG2) e Aflatoxin M1(AFM1) | IARC Group 1 | Liver cancer, immune system | Cereals (e.g., sorghum, rice, corn, wheat, barely), oil seed (e.g., cotton, rape, sunflower) nuts (e.g., peanuts, groundnut, pistachio), spices (e.g., turmeric, black and red pepper, ginger), meat, fruit juices, eggs, feed, and foods derived from these products. | <1 ng/g [38] | |
Ochratoxin A (OTA) | IARC Group 2B | Renal cancer, liver, cardiovascular and immune systems | Soya bean, nuts, red pepper, cereals, green coffee beans, coffee beans Grapes, red pepper, peanuts, cereals dry ham, salami | 4 ng/kg bw/day [39] | |
Fumonisins B1, B2 (FB1, FB2) | Hepatocarcinoma, stimulation and suppression of the immune system, defects in the neural-tube, nephrotoxicity | Peanut, maize, and grape, feed, and foods derived from these products | 2 μg/kg bw/day [40] | ||
Sterigmatocystin (STC) | Hepatocellular carcinomas, hemangiosarcomas of the liver and pulmonary adenomas | Cheese, spices (e.g., turmeric, black, white, red and chilli, pepper, cumin, and marjoram, caraway), cereals (barely, oat, wheat, corn, rice, buckwheat, soybean, sorghum) and derived from cereals (pastas, breakfast cereals) | 1.5 μg/kg [41] | ||
Fusarin C | Mutagen and immunosuppressive activities (comparable to aflatoxins B1 and sterigmatocystin) Human esophageal cancer [42] | Cereals (wheat, oats, barley, and maize), and fruit (banana and pineapple), lentils, tomato, and pea | No available data | ||
Deoxynivalenol (DON)1 | IARC Group 3 | Vomiting, digestive disorders and oxidative damage. Cytotoxicity and genotoxicity. | Wheat, barley, oats, rye, maize, rice, sorghum and triticale | PMTDI2, PDI3 1 μg/kg bw/day4 [43] | |
Zearalenone (ZEN) | Endocrine disruptor (interaction with estrogen-receptors) | Wheat, barley, oats, rye, and maize | PMTDI 0.5 μg/kg bw/day TDI5 0.25 μg/kg bw/day (20) [44] | ||
Citrinin (CIT) | Nephrotoxic6. Involved in induction of apoptosis though oxidative stress [45] | Mainly in stored grain. Benas, fruit, vegetables herbs and spices | |||
Patulin (PAT) | Gastrointestinal ulceration, immunotoxicity and neurotoxicity | Fruits especially apples silage | PMTDI 0.4 μg/kg bw/day [44] |
Main mycotoxins, toxic effect according to IARC, fungal species, frequently contaminated products, and maximum tolerable daily intake.
A recent study with 3000 Swedish students [47] evaluated the concentrations in urine of various mycotoxins, the data showed a worrying concentration of DON levels.
PMTDI, provisional maximum tolerable daily intake.
PDI, probable daily intake.
bw, body weight per day.
TDI, tolerable daily intake.
The co-occurrence with other mycotoxins, special ochratoxin A, is usually associated with endemic nephropathy.
EU MLs, European maximum levels (EFSA).
The action of mycotoxins as carcinogenic agents is explained by their chemical characteristics, which allow them to easily penetrate both in human and animal cells, reaching the genome, where they can cause mutations in the nucleotide sequence, which can lead to important and permanent alterations in the natural cellular processes of transcription and translation, giving rise to mutations that can exacerbate and deregulate cell growth [32].
According to the above, the study of mycotoxin toxicity goes beyond its carcinogenic and teratogenic effects; its local action in the various systems is of particular importance, aerial topical action at the level of the skin and respiratory system [48, 49, 50, 51, 52]. In the digestive system beyond its acute action at the level of vomiting and diarrhea, the effects on microbiota cause changes in the phylum, genus, and microbiota species level of the various animals exposed. The alterations of microbiota have an important consequence on health, as it causes alterations in the composition of short-chain volatile fatty acids and the sphingolipids normally present in the digestive tract; these alterations have been related to the appearance of several chronic diseases in human [35].
It is necessary to process food under standardized and well-controlled conditions and control each food production cycle and storage chain. Preventive measures capable of reducing contamination to a minimum must be implemented. If contamination occurs, methods to reduce or eliminate mycotoxins should be implemented independently of several parameters such as food or feed properties.
The prevalence of mycotoxin in food and feeds calls for the attention of food safety organizations to create awareness on their control and the need to put in place strict regulations to avoid high levels of exposure. Recent studies show that children may be exposed to mycotoxins from the time of breastfeeding resulting from the prevalence of mycotoxins in the mother’s diet [32].
In fact, food quality is a very broad concept, which, according to Jeantet et al. [53], covers five different components: safety, health, sensory, service, and society, which converge in numerous aspects and criteria. This categorization is much broader than the definition of food quality from the consumer’s point of view, which is much narrower, focusing mainly on sensory and health aspects [2]. Thus, when focusing on food quality, it is inevitable to mention food safety, which, in our view, is one of the fundamental bases for consuming quality food. The implementation and application of regulations and standards of good practice in production and processing, the application of sanitary controls, the design of production and processing facilities, and the continuous monitoring of all processes are elements that help reduce the risk of contamination and hygiene that can seriously compromise public health.
This research was funded by Fundação para a Ciência e a Tecnologia (FCT, Portugal), through projects UIDP/04567/2020 and UIDB/04567/2020. P.P. gratefully acknowledges the support of the CERENA strategic project FCT-UID/ECI/04028/2019.
The authors declare no conflict of interest.
The Open Access model is applied to all of our publications and is designed to eliminate subscriptions and pay-per-view fees. This approach ensures free, immediate access to full text versions of your research.
",metaTitle:"Open Access Publishing Fees",metaDescription:"Open Access Publishing Fees",metaKeywords:null,canonicalURL:"/page/OA-publishing-fees",contentRaw:'[{"type":"htmlEditorComponent","content":"As a gold Open Access publisher, an Open Access Publishing Fee is payable on acceptance following peer review of the manuscript. In return, we provide high quality publishing services and exclusive benefits for all contributors. IntechOpen is the trusted publishing partner of over 140,000 international scientists and researchers.
\\n\\nThe Open Access Publishing Fee (OAPF) is payable only after your book chapter, monograph or journal article is accepted for publication.
\\n\\nOAPF Publishing Options
\\n\\nDuring the launching phase journals do not charge an APC, rather they will be funded by IntechOpen.
\\n\\n*These prices do not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT as long as provision of the VAT registration number is made during the application process. This is made possible by the EU reverse charge method.
\\n\\nServices included are:
\\n\\nWhat isn't covered by the Open Access Publishing Fee?
\\n\\nIf your manuscript:
\\n\\nYour Author Service Manager will inform you of any items not covered by the OAPF and provide exact information regarding those additional costs before proceeding.
\\n\\nOpen Access Funding
\\n\\nTo explore funding opportunities and learn more about how you can finance your IntechOpen publication, go to our Open Access Funding page. IntechOpen offers expert assistance to all of its Authors. We can support you in approaching funding bodies and institutions in relation to publishing fees by providing information about compliance with the Open Access policies of your funder or institution. We can also assist with communicating the benefits of Open Access in order to support and strengthen your funding request and provide personal guidance through your application process. You can contact us at funders@intechopen.com for further details or assistance.
\\n\\nFor Authors who are still unable to obtain funding from their institutions or research funding bodies for individual projects, IntechOpen does offer the possibility of applying for a Waiver to offset some or all processing feed. Details regarding our Waiver Policy can be found here.
\\n\\nAdded Value of Publishing with IntechOpen
\\n\\nChoosing to publish with IntechOpen ensures the following benefits:
\\n\\nBenefits of Publishing with IntechOpen
\\n\\nAs a gold Open Access publisher, an Open Access Publishing Fee is payable on acceptance following peer review of the manuscript. In return, we provide high quality publishing services and exclusive benefits for all contributors. IntechOpen is the trusted publishing partner of over 140,000 international scientists and researchers.
\n\nThe Open Access Publishing Fee (OAPF) is payable only after your book chapter, monograph or journal article is accepted for publication.
\n\nOAPF Publishing Options
\n\nDuring the launching phase journals do not charge an APC, rather they will be funded by IntechOpen.
\n\n*These prices do not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT as long as provision of the VAT registration number is made during the application process. This is made possible by the EU reverse charge method.
\n\nServices included are:
\n\nWhat isn't covered by the Open Access Publishing Fee?
\n\nIf your manuscript:
\n\nYour Author Service Manager will inform you of any items not covered by the OAPF and provide exact information regarding those additional costs before proceeding.
\n\nOpen Access Funding
\n\nTo explore funding opportunities and learn more about how you can finance your IntechOpen publication, go to our Open Access Funding page. IntechOpen offers expert assistance to all of its Authors. We can support you in approaching funding bodies and institutions in relation to publishing fees by providing information about compliance with the Open Access policies of your funder or institution. We can also assist with communicating the benefits of Open Access in order to support and strengthen your funding request and provide personal guidance through your application process. You can contact us at funders@intechopen.com for further details or assistance.
\n\nFor Authors who are still unable to obtain funding from their institutions or research funding bodies for individual projects, IntechOpen does offer the possibility of applying for a Waiver to offset some or all processing feed. Details regarding our Waiver Policy can be found here.
\n\nAdded Value of Publishing with IntechOpen
\n\nChoosing to publish with IntechOpen ensures the following benefits:
\n\nBenefits of Publishing with IntechOpen
\n\n